These results suggest that in solid tumours, like primary and metastatic breast tumours, produced TGF-β most likely remains in the tumour microenvironment while in the case of AML, this growth factor is secreted into the peripheral blood and can be employed by circulating AML cells. This evidence concerns the gene TGFB1 and breast neoplasm.